Experimental Approaches to the Treatment of Schizophrenia
The Department welcomes Donald Goff, MD to Pittsburgh where he will present a Distinguished Scientist Lecture as part of our regular Friday series.
Dr. Goff is the Marvin Stern Professor of Psychiatry, Director of the Nathan S. Kline Institute, and Associate Director of the Institute for the Study of Decision Making (ISDM) at the New York University (NYU) School of Medicine. Dr. Goff is a translational clinical researcher who studies and treats schizophrenia. He pioneered the development of glutamatergic agents and folate supplementation for individuals with schizophrenia based on models from basic neuroscience and a personalized medicine approach. He is currently working in the areas of early intervention and the treatment of refractory symptoms employing strategies to enhance neuroprotection and neuroplasticity. Dr. Goff was the Director of the Schizophrenia Clinical and Research Program at the Massachusetts General Hospital and Professor of Psychiatry at Harvard Medical School prior to moving to New York in February 2012 to become Vice Chair for Research in Psychiatry at NYU Langone Medical Center and Director of the Nathan Kline Institute for Psychiatric Research. He has published over 200 articles on schizophrenia and related topics. Dr. Goff is the recipient of the Kempf Award for Mentorship in Biological Psychiatry from the American Psychiatric Association; the Wayne Fenton, MD, Award for Exceptional Clinical Care; the Stanley Dean Award for Research in Schizophrenia from the American College of Psychiatrists and the Research Award from the American Psychiatric Association. He is also a member of the American College of Neuropsychopharmacology and an Associate Editor of JAMA.
Date & Time. January 31, 2020, 12:00pm to 1:30pm
Location. UPMC Western Psychiatric Hospital Auditorium
For More Information. Please contact Frances Patrick at patrickfm@upmc.edu.
Learning Objectives. At the conclusion of Dr. Goff's lecture participants will be able to:
Understand the model of excessive hippocampal activation in early schizophrenia and the rationale for levetiracetam as an experimental treatment
Understand the model of impaired memory consolidation as a factor contributing to delusions and the rationale for D-cycloserine as an experimental treatment
Understand the model of hippocampal atrophy as a determinant of clinical course in early psychosis and the rationale for citalopram as an experimental treatment